CLBS Key Statistics, Chart & Performance
The current stock price of CLBS is 0.4264 USD. In the past month the price decreased by -21.05%. In the past year, price decreased by -64.47%.
CLBS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLBS. When comparing the yearly performance of all stocks, CLBS is a bad performer in the overall market: 84.2% of all stocks are doing better.
CLBS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLBS. The financial health of CLBS is average, but there are quite some concerns on its profitability.
CLBS Financial Highlights
Over the last trailing twelve months CLBS reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 52.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.61% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CLBS Forecast & Estimates
8 analysts have analysed CLBS and the average price target is 4.59 USD. This implies a price increase of 976.45% is expected in the next year compared to the current price of 0.4264.
CLBS Ownership
CLBS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.96 | 398.827B | ||
| AMGN | AMGEN INC | 16.25 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 12.01 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLBS
Company Profile
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Company Info
CALADRIUS BIOSCIENCES INC
110 Allen Road, Second Floor
Basking Ridge NEW JERSEY 07920 US
CEO: David J. Mazzo
Employees: 27
Phone: 19082292590.0
CALADRIUS BIOSCIENCES INC / CLBS FAQ
Can you describe the business of CALADRIUS BIOSCIENCES INC?
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Can you provide the latest stock price for CALADRIUS BIOSCIENCES INC?
The current stock price of CLBS is 0.4264 USD. The price decreased by -16.44% in the last trading session.
Does CALADRIUS BIOSCIENCES INC pay dividends?
CLBS does not pay a dividend.
How is the ChartMill rating for CALADRIUS BIOSCIENCES INC?
CLBS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CALADRIUS BIOSCIENCES INC (CLBS)?
CALADRIUS BIOSCIENCES INC (CLBS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the employee count for CLBS stock?
CALADRIUS BIOSCIENCES INC (CLBS) currently has 27 employees.